Patent Awarded for PET Radiopharmaceutical for Neurodegeneration Imaging

CereMark clinical research studies show that Flornaptitril binds with both tau aggregates and beta amyloid plaque in the brain to enhance PET scan imaging. The distribution patterns of these pathological proteins are significant in both Chronic Traumatic Encephalopathy (CTE)and Alzheimer’s Disease (AD). Through two phases of clinical research, several hundred subjects with cognitive impairment from either traumatic brain injuries or disease have been safely studied with Flornaptitril. CereMark has reached agreement with regulators on Phase 3 clinical investigational studies.

“Neurodegenerative brain disorders are a growing concern for doctors, patients and families, with everyone wanting to find better ways to address the needs of those patients presenting with mild to severe cognitive decline. We are excited that research we are accomplishing with Flornaptitril could represent a significant breakthrough in both diagnosis and charting responses to treatments, and better management for neurodegenerative diseases” said Dr. Henry M. Chilton, CEO of CereMark.

Additionally, Dr. William C. Putnam, Chief Regulatory and Science Officer commented “We are well positioned for continued success in the Phase 3 trial for Flornaptitril as no single PET imaging agent yet approved by FDA simultaneously detects both tau aggregates and beta amyloid plaque in neurodegeneration in a single scan. We are close to finalizing with FDA the protocol for our Phase 3 multi-site clinical trial for this truly unique PET imaging radiopharmaceutical.”

RELATED NEWS: The CereMark announced this week Dr. Donna J. Cross, an internationally recognized researcher in neurological pathology, has joined CereMark Pharma’s Medical and Science Advisory Board (MSAB). Dr. Cross, a principal investigator in research programs in Alzheimer’s disease, traumatic brain injuries, dementia, and aging, is an Associate Professor at the University of Utah’s Neuroimaging and Biotechnology Laboratory (NIBL). In addition, Dr. Cross was recently elected as President of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI)Brain Council. Dr. Cross joins other accomplished clinicians and researchers on CereMark’s MSAB, including:

• Dr.Satoshi Minoshima (Chairman, Department of Radiology, University of Utah; and past president of the Society of Nuclear Medicine and Molecular Imaging).

• Dr. John Lee (Chair, Neurosciences, NorthShore University HealthSystem; Editor-in-Chief, Journal of Neuropathology and Experimental Neurology).

• Dr. Edward Hall (Marksbery Chair in Neurotrauma Research, Spinal Cord and Brain Injury, University of Kentucky).